Evidence map›Paper›PMID 27198719›Full record

ArticleHaematologica2016

Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.

Lesley-Ann Sutton, Emma Young, Panagiotis Baliakas, Anastasia Hadzidimitriou, Theodoros Moysiadis, Karla Plevova, Davide Rossi, Jana Kminkova, Evangelia Stalika, Lone Bredo Pedersen and 26 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Stereotyped B-Cell Receptor Immunoglobulins in B-Cell Lymphomas.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 14 institutions in 10 countries.

Lesley-Ann SuttonDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Emma YoungDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Panagiotis BaliakasDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Anastasia HadzidimitriouInstitute of Applied Biosciences, CERTH, Thessaloniki, Greece.
Theodoros MoysiadisInstitute of Applied Biosciences, CERTH, Thessaloniki, Greece.
Karla PlevovaCentral European Institute of Technology, Masaryk University and University Hospital Brno, Czech Republic.
Davide RossiDivision of Haematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
Jana KminkovaCentral European Institute of Technology, Masaryk University and University Hospital Brno, Czech Republic.
Evangelia StalikaInstitute of Applied Biosciences, CERTH, Thessaloniki, Greece.
Lone Bredo PedersenDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Jitka MalcikovaCentral European Institute of Technology, Masaryk University and University Hospital Brno, Czech Republic.
Andreas AgathangelidisUniversità Vita-Salute San Raffaele, Milan, Italy Division of Experimental Oncology and Department of Onco-Hematology, IRCCS, San Raffaele Scientific Institute, Milan, Italy.
Zadie DavisDepartment of Haematology, Royal Bournemouth Hospital, Bournemouth, UK.
Larry MansouriDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Lydia ScarfòUniversità Vita-Salute San Raffaele, Milan, Italy Division of Experimental Oncology and Department of Onco-Hematology, IRCCS, San Raffaele Scientific Institute, Milan, Italy.
Myriam BoudjoghraHematology Department and University Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France.
Alba NavarroHematopathology Unit and Department of Hematology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi iSunyer (IDIBAPS), Barcelona, Spain.
Alice F MuggenDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Xiao-Jie YanThe Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, New York, NY, USA.
Florence Nguyen-KhacHematology Department and University Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France.
Marta LarrayozCancer Sciences, Faculty of Medicine, University of Southampton, UK.
Panagiotis PanagiotidisFirst Department of Propaedeutic Medicine, University of Athens, Greece.
Nicholas ChiorazziThe Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, New York, NY, USA.
Carsten Utoft NiemannDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Chrysoula BelessiHematology Department, Nikea General Hospital, Piraeus, Greece.
Elias CampoHematopathology Unit and Department of Hematology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi iSunyer (IDIBAPS), Barcelona, Spain.
Jonathan C StreffordCancer Sciences, Faculty of Medicine, University of Southampton, UK.
Anton W LangerakDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
David OscierDepartment of Haematology, Royal Bournemouth Hospital, Bournemouth, UK.
Gianluca GaidanoDivision of Haematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
Sarka PospisilovaCentral European Institute of Technology, Masaryk University and University Hospital Brno, Czech Republic.
Frederic DaviHematology Department and University Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France.
Paolo GhiaUniversità Vita-Salute San Raffaele, Milan, Italy Division of Experimental Oncology and Department of Onco-Hematology, IRCCS, San Raffaele Scientific Institute, Milan, Italy.
Kostas StamatopoulosDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden Institute of Applied Biosciences, CERTH, Thessaloniki, Greece Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Richard RosenquistDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden richard.rosenquist@igp.uu.se.
ERIC, the European Research Initiative on CLL
Uppsala University · SECentral European Institute of Technology · CZCentre for Research and Technology Hellas · GRSorbonne Université · FRConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESErasmus MC · NLNorthwell Health · USRigshospitalet · DKRoyal Bournemouth Hospital · GBUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Southampton · GBGeneral Hospital of Nikea · GRNational and Kapodistrian University of Athens · GRVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report on markedly different frequencies of genetic lesions within subsets of chronic lymphocytic leukemia patients carrying mutated or unmutated stereotyped B-cell receptor immunoglobulins in the largest cohort (n=565) studied for this purpose. By combining data on recurrent gene mutations (BIRC3, MYD88, NOTCH1, SF3B1 and TP53) and cytogenetic aberrations, we reveal a subset-biased acquisition of gene mutations. More specifically, the frequency of NOTCH1 mutations was found to be enriched in subsets expressing unmutated immunoglobulin genes, i.e. #1, #6, #8 and #59 (22-34%), often in association with trisomy 12, and was significantly different (P<0.001) to the frequency observed in subset #2 (4%, aggressive disease, variable somatic hypermutation status) and subset #4 (1%, indolent disease, mutated immunoglobulin genes). Interestingly, subsets harboring a high frequency of NOTCH1 mutations were found to carry few (if any) SF3B1 mutations. This starkly contrasts with subsets #2 and #3 where, despite their immunogenetic differences, SF3B1 mutations occurred in 45% and 46% of cases, respectively. In addition, mutations within TP53, whilst enriched in subset #1 (16%), were rare in subsets #2 and #8 (both 2%), despite all being clinically aggressive. All subsets were negative for MYD88 mutations, whereas BIRC3 mutations were infrequent. Collectively, this striking bias and skewed distribution of mutations and cytogenetic aberrations within specific chronic lymphocytic leukemia subsets implies that the mechanisms underlying clinical aggressiveness are not uniform, but rather support the existence of distinct genetic pathways of clonal evolution governed by a particular stereotyped B-cell receptor selecting a certain molecular lesion(s).

Indexed as

Biomarkers, TumorMutationComplementarity Determining RegionsCytogenetic AnalysisFemaleGene FrequencyGene Rearrangement, B-LymphocyteGenes, ImmunoglobulinHumansImmunoglobulin Heavy ChainsImmunoglobulin Joining RegionImmunoglobulin Variable RegionLeukemia, Lymphocytic, Chronic, B-CellMalePolymorphism, Single NucleotidePrognosisBiomarkers, TumorComplementarity Determining RegionsImmunoglobulin Heavy ChainsImmunoglobulin Joining RegionImmunoglobulin Variable RegionReceptors, Antigen, B-Cell

Identifiers

PMID27198719
PMCPMC4967575
OpenAlexW2407499086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.